August 6, Veterinarian Day in Argentina: origin of this date
August 6 is celebrated as Veterinarian Day in Argentina because on this date in 1883, the first classes of the Veterinary career began at the Santa Catalina Agricultural Institute in Llavallol, Buenos Aires Province.
The commemoration recognizes the work of professionals responsible for preventing, diagnosing, and treating diseases in pets, production animals, and wildlife, as well as participating in health campaigns, controlling conditions that can be transmitted to humans, and promoting scientific research.
Why is Veterinarian Day celebrated every August 6?
Veterinarian Day is celebrated every August 6 to remember the beginning of university education in veterinary medicine in Argentina.
On that day in 1883, the first classes of Agronomy and Veterinary careers officially started at the Santa Catalina Agricultural Institute, located in the Buenos Aires town of Llavallol, in the Lomas de Zamora district.
The establishment was promoted by Eduardo Olivera, an Argentine agronomist who had completed his training in France and advocated for the modernization of the agricultural sector through higher education.
The first academic cycle had 17 students, a number that increased the following year. The first classes were taught by teachers such as Luciano Garola, Pablo Lavenir, Eduardo Losson, Gustavo Rieder, Víctor Even, Alejandro Tribout, and Eugenio Vermersch.
In 1887, the first three veterinarians trained in the country graduated. In 1889, the National Congress ordered the transfer of the institution to the city of La Plata, where it became the Faculty of Agronomy and Veterinary of the Province of Buenos Aires.
The commemoration was officialized in 1993 by a decree signed by then-president Raúl Alfonsín.
Branches of veterinary medicine and main functions
Each branch of veterinary medicine responds to specific needs and requires specialized knowledge to address different species or solve health problems. Among them are:
Companion animal medicine
This is the most well-known specialty among the population. It focuses on the diagnosis, treatment, and prevention of diseases in dogs, cats, and other pets.
Professionals perform clinical checks, administer vaccines, deworm, attend to emergencies, perform surgeries, prescribe treatments, and support owners through all stages of their animals' lives. They also advise on nutrition, behavior, responsible breeding, and care.
Large animal veterinary
This branch mainly deals with cattle, horses, sheep, goats, and pigs, species for agricultural production.
Veterinarians work in rural establishments monitoring the health status of herds, preventing diseases, supervising births, improving reproduction, and implementing vaccination plans.
Animal production
Veterinary specialists in production collaborate with agricultural producers to improve the efficiency of breeding systems while ensuring animal welfare.
Their work includes feeding programs, reproductive control, genetics, health management, disease prevention, and optimization of production processes to guarantee safe and quality food.
Public Veterinary Health
This is one of the most important areas due to its direct impact on society. Veterinarians participate in the control of zoonotic diseases, which are those that can be transmitted from animals to humans, such as rabies, brucellosis, leptospirosis, or trichinosis.
They collaborate in vaccination campaigns, epidemiological surveillance, and prevention driven by official agencies. Additionally, they inspect places where animal-derived food is produced to verify compliance with sanitary regulations.
Exotic Animal Medicine
This field focuses on birds, reptiles, amphibians, small mammals, and other species that are increasingly common as pets.
Due to the particular characteristics of these species, veterinarians must understand their nutritional, physiological, and environmental needs to diagnose diseases and establish appropriate treatments.
Wildlife and Conservation
Veterinarians play a fundamental role in the preservation of biodiversity: they work in natural reserves, national parks, zoos, rescue centers, and conservation programs.
They care for injured animals, rehabilitate specimens for reintroduction into their natural habitat, and participate in research aimed at protecting endangered species.
Clinical Specialties
Similar to human medicine, veterinary medicine has numerous specialties.
Among the main ones are:
- Internal Medicine.
- General and high-complexity Surgery.
- Dermatology.
- Cardiology.
- Neurology.
- Traumatology and Orthopedics.
- Oncology.
- Ophthalmology.
- Endocrinology.
- Gastroenterology.
- Veterinary Dentistry.
- Imaging Diagnostics.
- Anesthesiology.
- Rehabilitation and Physiotherapy.
- Clinical Nutrition.
Scientific Research and Teaching
Many veterinarians develop their careers in universities, research institutes, and laboratories. They participate in studies on diseases, vaccine development, medications, diagnostic techniques, genetics, reproduction, and animal welfare.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Now Accepting Bitcoin: 425 Los Angeles Bitcoin Merchants Featuring Café De Leche

Inside CZ's Haven: Exploring the Life Behind the Most Powerful Figure in Crypto

The 'Roller Effect' of AI and the 'Workshopization' of Software as a Prelude to the Internet of Intelligent Agents

What Are Other Chains Doing Amidst the Hype of Robinhood?

Some establishments are likely to be closed

MARVIN Mars Dog Announces 40% Token Buyback and Burn Plan

Non-consensus Decisions in the Robotics Sector: Why Sequoia Chose to Double Down on Yushu at Its Most Difficult Time?

Trial for Loan Peña: New Hearing with Three Witnesses in Corrientes

12 Dachshund Puppies Rescued at Argentina-Uruguay Border

Approved Welfare Protocol for Federal Police Dogs

Ardoino’s 24/7 asset plan depends on buyers willing to wait for cash

Wallets, fintechs, and platforms target the freelancer market: why Argentina is a key market

Greece ends years of crypto tax uncertainty with new 10% levy on Bitcoin profits

Ethereum software bug triggers emergency fixes across major layer-2 networks

Kraken Owner Invests in Altcoin, Considers Further Purchases. You Should Recognize Him

Stablecoins offer sub-cent payments, Armstrong says, as critics flag risks

Analysis: Stablecoins, Payments, and Prediction Markets Have Become New Growth Points for Crypto Companies, but Profitability Remains Challenged

Nubank Suspends Crypto Withdrawals: What We Know So Far

Buffett's Successor Faces Setback, Google Holdings Show $3 Billion Unrealized Loss

Banking Outage in Japan: 128 Banks 'Frozen' at Once

Beyond APY: Saying Goodbye to Black Box Trust and Reassessing the Security Logic of ETH Staking

Argentine Bitcoiners Debut “The Genesis Of Satoshi Nakamoto” Artwork In Downtown Buenos Aires

Broadcom (AVGO) : AI Growth, Fund Positioning, and Guarantee Risk
Broadcom (AVGO) recently fell with the semiconductor sector, closing down 10.43% at $291.53 on November 5. The shares rebounded more than 4% in premarket trading on November 6. Concerns that election results could lead to tighter AI rules and slower data center approvals contributed to a broad sell-off, with a semiconductor index falling about 12%. The move appears tied mainly to sector sentiment and policy concerns, with no clear company-specific negative catalyst identified.
Institutional trading and AI growth expectations are also in focus. ARK funds sold about $134 million of Broadcom shares over two sessions while adding to SpaceX. Citi maintained its Buy rating and projected that Broadcom’s AI semiconductor revenue could reach $115 billion in fiscal 2027, roughly doubling year over year. Broadcom had approximately $179.2 billion in signed contracts as of the prior quarter, while analysts estimated fourth-quarter AI chip revenue at about $21.7 billion. These forecasts will need to be tested against future results.
Contingent guarantees are another point for investors to monitor. Broadcom is providing guarantees tied to Anthropic’s AI rack-leasing arrangement, involving about $29 billion in the first phase and a second-phase plan of up to $43 billion. Banks plan to issue $21 billion in bonds to support related chip financing. The guarantee amounts are not the same as debt already incurred, but they add a potential risk to assess. Broadcom is scheduled to report its next quarterly results on December 9, when management’s outlook for fiscal 2027 AI demand will be closely watched. This article is for informational purposes only and is not investment advice.

Netflix (NFLX) Stock Rebounds: Insider Sales, Advertising, and Growth Plans
Several Netflix executives sold company shares in early November 2026. Co-CEO Theodore Sarandos sold 27,312 shares from November 3 to 4, valued at about $1.81 million. CFO Spencer Neumann sold shares worth approximately $612,000. Co-CEO Gregory Peters realized about $1.69 million, including transactions related to tax withholding. Chief Legal Officer David Hyman and director Bradford Smith also reduced their holdings. Executive sales can have different reasons and should not be viewed on their own as a measure of the company’s outlook.
After recent pressure, Netflix shares rebounded more than 4% around November 4. Bill Ackman’s Pershing Square Capital Management allocated about 5% of its portfolio to Netflix, while new AI features and positive views on the company’s technology prospects helped sentiment. Netflix reported third-quarter 2026 revenue of $13.44 billion and earnings per share of $0.87, both above expectations, though its forward outlook remains a key focus.
Advertising is one of Netflix’s main challenges. Delays to key ad product features led the company to reduce its annual advertising revenue outlook from $3 billion to $2.7 billion. Viewer engagement has also faced pressure from changes in content appeal and competition from platforms such as YouTube. Netflix is pursuing growth through live events, gaming, and advertising, with plans to expand its ad-supported offering to 15 markets while adjusting its workforce by about 6% to improve margins. Investors may want to monitor advertising growth, engagement, and profitability. This article is for informational purposes only and is not investment advice.

Carvana Earnings: Record Sales, Strong Profit, and Insider Share Sales
Carvana reported third-quarter net revenue of $8.04 billion, up 42.4% year over year and above the $7.7 billion market estimate. Retail units sold reached a record 217,385, an increase of 39.4%. Net income rose to $483 million, while adjusted EBITDA reached a record $800 million, reflecting gains in both revenue and profitability.
Management expects full-year 2026 adjusted EBITDA to reach the upper end of its $2.7 billion to $3.0 billion range. Needham maintained its Buy rating, named Carvana a top pick in transportation technology, and set a $100 price target. Strong results and guidance have drawn investor attention, though continued performance will depend on sales, margins, and operating costs.
Insider transactions are also on investors’ radar. A regulatory filing indicates that CFO Mark Jenkins planned to sell 63,800 shares on November 2, 2026, valued at approximately $4.35 million. Since August, he has planned sales totaling 191,300 shares. An executive share sale alone does not determine a company’s outlook; investors may also consider earnings, cash flow, and future guidance. This article is for informational purposes only and is not investment advice.

FCEL Stock: Data Center Opportunity, Manufacturing Costs, and Lawsuit Risk
FuelCell Energy (ticker: FCEL) provides fuel-cell power solutions. Growing electricity demand from AI data centers could create new business opportunities, while proposed pauses on new data center approvals in some areas have raised concerns about project timelines. A 75-megawatt power project may be affected, and FCEL shares recently fell as much as about 17% in a single session amid policy concerns.
FCEL signed an agreement with Fit Energy to provide up to 380 megawatts of fuel-cell power solutions. Its backlog is approximately $3.6 billion, with about 97% of its sales pipeline related to data centers. The company also drew the second installment under a $49 million financing arrangement backed by an export credit agency, supporting a green energy project and clean-energy exports. Recent leadership changes include Matthew Latino becoming CFO, digital infrastructure executive Peter Hopper joining the board, and John Dansby leading manufacturing scale-up. Converting orders into revenue will depend on production capacity, costs, and project execution.
FCEL reported third-quarter revenue of about $33 million, down approximately 29% year over year, and a net loss of roughly $45.3 million. Product costs and manufacturing overhead for the Fit Energy agreement exceeded the contract pricing, resulting in an approximately $17 million contract impairment charge. Securities class-action allegations concern disclosures about manufacturing capacity and costs; the case remains in the legal process. The deadline to seek appointment as lead plaintiff is November 10, 2026. FCEL’s growth opportunities come with execution, financing, and litigation risks. This article is for informational purposes only and is not investment advice.

Democratic Party's AI Regulation Push Revealed: Plans for Intensive Legislation and Strict Scrutiny of Tech Giants

PFE Stock: Pfizer’s Q3 2026 Earnings, Business Strategy, and Dividend Outlook
PFE is the New York Stock Exchange ticker for Pfizer Inc. In the third quarter of 2026, Pfizer reported revenue of $16.58 billion and adjusted earnings per share of $0.87, both above market expectations. The company raised its full-year revenue outlook to $62 billion–$64 billion and its adjusted EPS guidance to $2.95–$3.05, pointing to stronger performance than previously expected.
Although demand for COVID-related products continues to decline, Pfizer’s non-COVID business is growing. Third-quarter sales reached $720 million for the cancer drug Padcev and $2.52 billion for Eliquis, up 25% year over year. Revenue from newer and acquired products rose 32%. Pfizer is expanding its oncology pipeline, entering the weight-loss treatment market through its acquisition of Metsera, and targeting approximately $9.7 billion in net cost savings by 2029. Cecile Guegan has also taken over as chief financial officer.
Investors are also watching Pfizer’s dividend and legal developments. The company declared a cash dividend of $0.43 per share, with an ex-dividend date of November 6, 2026. Analysts raised some earnings estimates and price targets following the quarterly results. Pfizer also faces ongoing legal scrutiny related to statements about COVID vaccine safety, while its subsidiary Mylan has sued Novo Nordisk over generic-drug patent issues involving Wegovy. Pfizer’s outlook depends on new-product growth, cost savings, patent matters, and litigation developments. This article is for informational purposes only and is not investment advice.

South Korea’s GOPAX halts crypto trading, withdrawals after hacking threat










